BLCO vs HSIC vs ATRC vs HOLX vs SYK

For growth investors, AtriCure, Inc.

(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate AtriCure, Inc. (ATRC) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 7x versus Stryker Corporation at 34. 0x. On forward P/E, Henry Schein, Inc. is actually cheaper at 13. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Henry Schein, Inc. 's 4. 20x — a reasonable growth-adjusted valuation.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +17.

5%, compared to -64. 2% for AtriCure, Inc. (ATRC). Over 10 years, the gap is even starker: SYK returned +179. 2% versus BLCO's -19. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 45β versus Bausch + Lomb Corporation's 1. 36β — meaning BLCO is approximately 201% more volatile than HOLX relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 82% for Bausch + Lomb Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AtriCure, Inc.

(ATRC) is pulling ahead at 14. 9% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hologic, Inc.

(HOLX) is the more profitable company, earning 13. 8% net margin versus -7. 1% for Bausch + Lomb Corporation — meaning it keeps 13. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -0. 6% for ATRC. At the gross margin level — before operating expenses — ATRC leads at 74. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Henry Schein, Inc. 's 4. 20x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Henry Schein, Inc. (HSIC) trades at 13. 2x forward P/E versus 428. 7x for AtriCure, Inc. — 415. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 95. 3% to $51. 33.

In this comparison, SYK (1.

2% yield) pays a dividend. BLCO, HSIC, ATRC, HOLX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, BLCO: -19. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

SYK pays a dividend while BLCO, HSIC, ATRC, HOLX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.